[68Ga]Ga-DOTA-Cys-ATH001

N/A

Report date: 2025/11/20 16:00:32
NME

Base Information

Drug Name[68Ga]Ga-DOTA-Cys-ATH001
Drug Alias Name[68Ga]Ga-DOTA-Cys-ATH001
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionPositron-emission tomography enhancersPlatelet-derived growth factor receptor beta modulators
TargetsPlatelet-derived growth factor receptor beta
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCrohn DiseaseCholangitis, Sclerosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAntaros Medical Ab
China Registration ClassN/A

Develop Information

Active CompaniesAntaros Medical AbTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCrohn DiseaseCholangitis, Sclerosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A